OBJECTIVES: The principal aim of the study was to verify whether HPV infection in healthy women, as determined by HPV DNA detection, was associated with an increased risk of development of cervical lesions. METHODS: Cervical smears collected at enrolment into the prospective study conducted in Prague during 1975-83 were tested for the presence of HPV DNA by means of a polymerase chain reaction (PCR) using the general GP5/6 primers and a mixture of primers specific for the E6 gene. 120 smears from patients in whom cervical neoplasia had been detected in the course of the prospective study and 208 smears from control women who had remained healthy throughout the observation period were analysed. Patients and controls were matched by age, number of sexual partners, age at first intercourse, and smoking habit. Patients were divided into three groups, A, B, and C, according to their cytological, colposcopic, and histological findings at enrolment. Group A consisted of 67 women found ill at enrolment, group B of 26 women with slightly suspicious findings, while group C comprised 27 women with normal findings at enrolment. In addition, sera taken at enrolment from these patients and controls were tested for the presence of antibodies reactive with virus-like particles (VLPs) of HPV 16, 18, and 33. RESULTS: For the whole cohort, there was a statistically highly significant difference in the presence of HPV DNA between patients and controls. Furthermore, the difference in the presence of HPV DNA between patients and controls was highly significant not only in those who had been found ill at enrolment (group A) but, most importantly, also in women who had developed the disease in the course of the follow up (groups B and C). Women positive for HPV DNA possessed HPV antibodies to VLP16, 18 and 33 significantly more often than those who were free of HPV DNA. CONCLUSION: This indicated that healthy women who were positive for HPV DNA at enrolment were at an increased risk of developing cervical neoplasia (OR = 18.5; CI 5.9 to 57.6).

Department of Experimental Virology Institute of Hematology and Blood Transfusion Prague Czech Republic

See more in PubMed

J Infect Dis. 2000 Jun;181(6):1911-9 PubMed

JAMA. 1991 Jan 23-30;265(4):472-7 PubMed

Sex Transm Infect. 2003 Apr;79(2):85-7 PubMed

Acta Virol. 1967 Jul;11(4):372-8 PubMed

Proc Soc Exp Biol Med. 1970 Nov;135(2):543-5 PubMed

Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5 PubMed

Int J Cancer. 1984 Jan 15;33(1):49-60 PubMed

Int J Cancer. 1984 Jan 15;33(1):61-6 PubMed

Nature. 1985 Mar 7-13;314(6006):111-4 PubMed

J Gen Virol. 1985 Jul;66 ( Pt 7):1515-22 PubMed

Science. 1985 Dec 20;230(4732):1350-4 PubMed

Int J Cancer. 1986 Aug 15;38(2):161-5 PubMed

J Natl Cancer Inst. 1994 Apr 6;86(7):494-9 PubMed

Biochem Biophys Res Commun. 1994 Oct 28;204(2):820-7 PubMed

J Infect Dis. 1994 Dec;170(6):1424-31 PubMed

Intervirology. 1994;37(3-4):168-79 PubMed

Obstet Gynecol. 1995 Mar;85(3):337-42 PubMed

Int J Cancer. 1995 May 4;61(3):306-11 PubMed

J Infect Dis. 1995 Jul;172(1):19-24 PubMed

J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71 PubMed

BMJ. 1996 Mar 2;312(7030):537-9 PubMed

Int J Cancer. 1991 May 30;48(3):404-8 PubMed

J Gen Virol. 1991 Nov;72 ( Pt 11):2781-6 PubMed

Int J Cancer. 1993 Apr 1;53(6):919-23 PubMed

Int J Cancer. 1994 Mar 15;56(6):802-6 PubMed

Int J Cancer. 1996 Mar 1;65(5):601-6 PubMed

Int J Cancer. 1996 Mar 28;66(1):70-4 PubMed

J Infect Dis. 1996 Nov;174(5):927-36 PubMed

J Clin Oncol. 1997 Feb;15(2):610-9 PubMed

J Natl Cancer Inst. 1997 May 7;89(9):630-8 PubMed

J Natl Cancer Inst. 1997 Sep 3;89(17):1293-9 PubMed

Int J Cancer. 1999 Jan 29;80(3):365-8 PubMed

J Natl Cancer Inst. 1999 Jun 2;91(11):954-60 PubMed

J Med Virol. 1999 Aug;58(4):378-86 PubMed

J Pathol. 1999 Sep;189(1):12-9 PubMed

J Virol. 1990 Feb;64(2):813-21 PubMed

J Gen Virol. 1990 Jan;71 ( Pt 1):173-81 PubMed

Sex Transm Infect. 2002 Oct;78(5):374-7 PubMed